FDA accepts Teva’s application for Uzedy for bipolar I disorder

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy extended-release injectable suspension as a maintenance treatment for bipolar I disorder, or BP-I, in adults.

The drug, also known as risperidone, is currently approved